HR and breast carcinoma: Endocrine therapy (ET), with either fulvestrant (Fulv) or aromatase inhibitors (AIs), plus a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) is the recommended first-line standard of care for patients with HR+/HER2- advanced breast cancer [7].